Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
|Videos|June 11, 2019
Dr. Daniel George on the Treatment Landscape for RCC
Author(s)Daniel George, MD
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Advertisement
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5